The predictive value of transforming growth factor-β in Wilms tumor immunopathogenesis

References

• Yaqub S, Aandahl EM. Inflammation versus adaptive immunity in cancer pathogenesis. Critical Reviews in Oncogenesis; 2009;15(1–2):43–63.
   Google Scholar
• Fridman WH, et al. Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 2011;344:1–24.
   PubMed Web of Science ®Google Scholar
• Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345(11):833–835.
   PubMed Web of Science ®Google Scholar
• Rivera MN, Haber DA. Wilms tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer 2005;5(9):699–712.
   PubMed Web of Science ®Google Scholar
• Fabregat I, et al. TGF-beta signaling in cancer treatment. Curr Pharm Des 2014;20(17):2934–2947.
   PubMed Web of Science ®Google Scholar
• Zhang L, et al. Expression of TGF-beta1 in Wilms tumor was associated with invasiveness and disease progression. J Pediatr Urol 2014;10(5):962–968.
   PubMed Web of Science ®Google Scholar
• Zirn B, et al. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 2005;24(33):5246–5251.
   PubMed Web of Science ®Google Scholar
• Davidoff AM. Wilms tumor. Adv Pediatr 2012;59(1):247–267.
   PubMedGoogle Scholar
• Breslow NE, et al. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor. Pediatr Blood Cancer 2006;47(3):260–267.
   PubMed Web of Science ®Google Scholar
• Society AC. Cancer facts and figures 2015. Atlanta: GA: American Cancer Society; 2015.
   Google Scholar
• Kaste SC, et al. Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr Radiol 2008;38(1):2–17.
   PubMed Web of Science ®Google Scholar
• Hadley LG, Rouma BS, Saad-Eldin Y. Challenge of pediatric oncology in Africa. Semin Pediatr Surg 2012;21(2):136–141.
   PubMed Web of Science ®Google Scholar
• Stones DK, et al. The impact of ethnicity on Wilms tumor: characteristics and outcome of a South African cohort. Int J Pediatr 2015;2015:706058.
   PubMedGoogle Scholar
• Kalapurakal JA, et al. Management of Wilms tumour: current practice and future goals. Lancet Oncol 2004;5(1):37–46.
   PubMed Web of Science ®Google Scholar
• Call KM, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell 1990;60(3):509–520.
   PubMed Web of Science ®Google Scholar
• Hoglund M, et al. Wilms tumors develop through two distinct karyotypic pathways. Cancer Genet Cytogenet 2004;150(1):9–15.
   PubMedGoogle Scholar
• Scott RH, et al. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 2006;43(9):705–715.
   PubMed Web of Science ®Google Scholar
• Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 2008;47(6):461–470.
   PubMed Web of Science ®Google Scholar
• Perotti D, et al. Functional inactivation of the WTX gene is not a frequent event in Wilms tumors. Oncogene 2008;27(33):4625–4632.
   PubMed Web of Science ®Google Scholar
• Satoh Y, et al. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms tumours. Br J Cancer 2006;95(4):541–547.
   PubMed Web of Science ®Google Scholar
• Bjornsson HT, et al. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst 2007;99(16):1270–1273.
   PubMedGoogle Scholar
• Huff V. Wilms tumor genetics. Am J Med Genet 1998;79(4):260–267.
   PubMed Web of Science ®Google Scholar
• Nakadate H, et al. Mutations/deletions of the WT1 gene, loss of heterozygosity on chromosome arms 11p and 11q, chromosome ploidy and histology in Wilms tumors in Japan. Int J Cancer 2001;94(3):396–400.
   PubMed Web of Science ®Google Scholar
• Sugiyama H. WT1 (Wilms tumor gene (1): biology and cancer immunotherapy. Jpn J Clin Oncol 2010;40(5):377–387.
   PubMed Web of Science ®Google Scholar
• Bardeesy N, et al. Anaplastic Wilms tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 1994;7(1):91–97.
   PubMed Web of Science ®Google Scholar
• Medler TR, Cotechini T, Coussens LM. Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer 2015;1(1):66–75.
   PubMedGoogle Scholar
• Selleri S, et al. Tumor microenvironment and the immune response. Surg Oncol Clin N Am 2007;16(4):737–753, vii–viii.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Mantovani A, et al. Cancer-related inflammation. Nature 2008;454(7203):436–444.
   PubMed Web of Science ®Google Scholar
• Maturu P, et al. Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in Wilms tumors. Transl Oncol 2014;7(4):484–492.
   PubMed Web of Science ®Google Scholar
• Colotta F, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009;30(7):1073–1081.
   PubMed Web of Science ®Google Scholar
• Vakkila J, et al. Pediatric cancers are infiltrated predominantly by macrophages and contain a paucity of dendritic cells: a major nosologic difference with adult tumors. Clin Cancer Res 2006;12(7, Pt 1):2049–2054.
   PubMed Web of Science ®Google Scholar
• Liou P, et al. Correlation of tumor-associated macrophages and clinicopathological factors in Wilms tumor. Vasc Cell 2013;5(1):5.
   PubMedGoogle Scholar
• Timofeeva OA, et al. Serine-phosphorylated STAT1 is a prosurvival factor in Wilms tumor pathogenesis. Oncogene 2006;25(58):7555–7564.
   PubMed Web of Science ®Google Scholar
• Wang H, et al. STAT1 activation regulates proliferation and differentiation of renal progenitors. Cell Signal 2010;22(11):1717–1726.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang L, Wu R. Differential expression of STAT1 and IFN-gamma in primary and invasive or metastatic Wilms tumors. J Surg Oncol 2013;108(3):152–156.
   PubMed Web of Science ®Google Scholar
• Maturu P. The inflammatory microenvironment in Wilms tumors. In: Heuvel-Eibrink MMvd, editor. Wilms tumor. Brisbane, Australia: Codon; 2016:189–207.
   Google Scholar
• Eckschlager T, et al. Changes of blood count, lymphocyte subpopulations and immunoglobulin levels in nephroblastoma long-term survivors. Neoplasma 2009;56(1):9–12.
   PubMed Web of Science ®Google Scholar
• Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008;134(3):392–404.
   PubMed Web of Science ®Google Scholar
• Rubtsov YP, Rudensky AY. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 2007;7(6):443–453.
   PubMed Web of Science ®Google Scholar
• Weinberg R. The biology of cancer, 2nd ed. Garland Science: New York; pp. 311–313. 2013.
   Google Scholar
• Paltridge JL, Belle L, Khew-Goodall Y. The secretome in cancer progression. Biochim Biophys Acta 2013;1834(11):2233–2241.
   PubMed Web of Science ®Google Scholar
• Pardali K, Moustakas A. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 2007;1775(1):21–62.
   PubMed Web of Science ®Google Scholar
• Massague J, et al. Affinity labeling of a transforming growth factor receptor that does not interact with epidermal growth factor. Proc Natl Acad Sci USA 1982;79(22):6822–6826.
   PubMed Web of Science ®Google Scholar
• Massague J, Like B. Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem 1985;260(5):2636–2645.
   PubMed Web of Science ®Google Scholar
• Pennison M, Pasche B. Targeting transforming growth factor-beta signaling. Curr Opin Oncol 2007;19(6):579–585.
   PubMed Web of Science ®Google Scholar
• Bierie B, Moses HL. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 2009;8(20):3319–3327.
   PubMed Web of Science ®Google Scholar
• Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003;3(11):807–821.
   PubMed Web of Science ®Google Scholar
• Parvani JG, Taylor MA, Schiemann WP. Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 2011;16(2):127–146.
   PubMed Web of Science ®Google Scholar
• Kang Y, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 2005;102(39):13909–13914.
   PubMed Web of Science ®Google Scholar
• Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006;25(3):435–457.
   PubMed Web of Science ®Google Scholar
• Wakefield LM, Roberts AB. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12(1):22–29.
   PubMed Web of Science ®Google Scholar
• Nagaraj NS, Datta PK. Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 2010;19(1):77–91.
   PubMed Web of Science ®Google Scholar
• Lebrun J-J. The dual role of TGF in human cancer: from tumor suppression to cancer metastasis. ISRN Mol Biol 2012;2012:28.
   Google Scholar
• Massague J. TGFbeta in cancer. Cell 2008;134(2):215–230.
   PubMed Web of Science ®Google Scholar
• Akhurst RJ, Derynck R. TGF-beta signaling in cancer – a double-edged sword. Trends Cell Biol 2001;11(11):S44–S51.
   PubMed Web of Science ®Google Scholar
• Morris JC, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 2014;9(3):e90353.
   PubMed Web of Science ®Google Scholar
• Bogdahn U, et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011;13(1):132–142.
   PubMed Web of Science ®Google Scholar
• Serova M, et al. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients. Oncotarget 2015;6(25):21614–21627.
   PubMed Web of Science ®Google Scholar
• Stevenson JP, et al. Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology 2013;2(8):e26218.
   PubMed Web of Science ®Google Scholar
• Sakairi T, Abe Y, Kopp JB. TGF-beta1 reduces Wilms tumor suppressor gene expression in podocytes. Nephrol Dial Transplant 2011;26(9):2746–2752.
   PubMed Web of Science ®Google Scholar
• Lee HS. Mechanisms and consequences of TGF-ss overexpression by podocytes in progressive podocyte disease. Cell Tissue Res 2012;347(1):129–140.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270(5244):2008–2011.
   PubMed Web of Science ®Google Scholar
• Kim SI, et al. TGF-beta-activated kinase 1 is crucial in podocyte differentiation and glomerular capillary formation. J Am Soc Nephrol 2014;25(9):1966–1978.
   PubMed Web of Science ®Google Scholar
• Lu J, et al. Analyzing the gene expression profile of anaplastic histology Wilms tumor with real-time polymerase chain reaction arrays. Cancer Cell Int 2015;15:44.
   PubMed Web of Science ®Google Scholar
• Park CY, et al. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer 2011;47(17):2642–2653.
   PubMed Web of Science ®Google Scholar
• Matise LA, et al. Lack of transforming growth factor-beta signaling promotes collective cancer cell invasion through tumor-stromal crosstalk. Breast Cancer Res 2012;14(4):R98.
   PubMed Web of Science ®Google Scholar
• Lin W, et al. Pien Tze Huang inhibits liver metastasis by targeting TGF-beta signaling in an orthotopic model of colorectal cancer. Oncol Rep 2015;33(4):1922–1928.
   PubMed Web of Science ®Google Scholar
• Pendaries V, et al. Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner. Oncogene 2003;22(50):8212–8220.
   PubMed Web of Science ®Google Scholar
• Ross SA, et al. Retinoids in embryonal development. Physiol Rev 2000;80(3):1021– 1054.
   PubMed Web of Science ®Google Scholar
• Ghanem MA, et al. MIB-1 (KI-67) proliferation index and cyclin-dependent kinase inhibitor p27(Kip1) protein expression in nephroblastoma. Clin Cancer Res 2004;10(2):591– 597.
   PubMed Web of Science ®Google Scholar
• Ghanem MA, et al. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Br J Cancer 2001;85(10):1557–1563.
   PubMed Web of Science ®Google Scholar
• Ghanem MA, et al. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003;56(2):107–113.
   PubMed Web of Science ®Google Scholar
• Szychot E, Apps J, Pritchard-Jones K. Wilms tumour: biology, diagnosis and treatment. Transl Pediatr 2014;3(1):12–24.
   PubMedGoogle Scholar